P Peptide Calculator
Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
MariTide (AMG-133) and BAC Water Mix

MariTide (AMG-133) Reconstitution Calculator

Reviewed by · Pharmacist and Scientific Reviewer

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example MariTide (AMG-133) Titration Schedule

ParameterDetails
Phase 3 escalation21 → 35 → 70 mg (8 weeks)
Phase 3 targets140 / 210 / 350 mg
FrequencySC once monthly
Half-life~21 days
Duration72 weeks (Phase 3)

Investigational. Half-life is approximately 21 days (not 13–17) and Phase 3 runs 72 weeks (not 104); the full escalation is four levels, not three. A peptide-antibody conjugate — it cannot be replicated by standard peptide synthesis.

Possible vial strengths:

What Is It?

MariTide (AMG-133)

GLP-1 agonist / GIPR antagonist conjugate.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix MariTide (AMG-133)

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

MariTide (AMG-133) Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

MariTide, also called maridebart cafraglutide or AMG 133, is an investigational obesity drug from Amgen. It is a long-acting antibody-peptide conjugate designed for monthly or less frequent dosing, but it is not FDA-approved or commercially available.
MariTide activates the GLP-1 receptor while blocking the GIP receptor. That is different from tirzepatide, which activates both GLP-1 and GIP receptors, making MariTide a distinct incretin-based approach rather than a copy of existing GLP-1/GIP drugs.
A calculator can only show concentration math, not a clinical dosing plan. For example, if a hypothetical 420 mg research vial is brought to 7 mL final volume, the concentration is 60 mg/mL; 140 mg equals 2.33 mL, 280 mg equals 4.67 mL, and 420 mg equals 7.00 mL.
Yes. Amgen has multiple Phase 3 MARITIME studies evaluating MariTide for chronic weight management and obesity-related conditions. Phase 3 status does not mean approval; MariTide is still investigational until regulators review and approve it.
Tirzepatide is a GLP-1/GIP dual agonist given weekly, while MariTide combines GLP-1 activation with GIP receptor blocking and is being studied for monthly or less frequent dosing. The tradeoff is that tirzepatide is already approved, while MariTide still needs Phase 3 outcomes and regulatory review.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

More GLP-1 & Metabolic calculators

Retatrutide Semaglutide Tirzepatide Liraglutide CagriSema Cagrilintide Mazdutide Survodutide

References

  1. Eapen D, et al. MariTide (AMG-133) in adults with obesity. N Engl J Med. 2025.

About the author

· Pharmacist and Scientific Reviewer

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides